Biotech | December 08, 2021
SPARC partners with Visiox for ophthalmic drugs
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
The company has posted net loss of Rs. 99.54 crores for the period ended March 31, 2020
The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day
The company will review FDA's response and decide on appropriate next steps soon.
Subscribe To Our Newsletter & Stay Updated
